Priority 5 from the Multiple Sclerosis PSP

UNCERTAINTY: Does early treatment with aggressive disease modifying drugs improve the prognosis for people with multiple sclerosis? (JLA PSP Priority 5)
Overall ranking 5
JLA question ID 0016/5
Explanatory note Existing relevant systematic reviews are not up-to-date

No evidence found

Systematic reviews that need extending or updating

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009882. DOI: 10.1002/14651858.CD009882.pub2.

Systematic reviews in preparation

No evidence found

Ongoing controlled trials

Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome D-Lay-MS NCT01817166 Dose-related effects of Vitamin D3 on immune responses in patients with clinically isolated syndrome CISAVID NCT01728922

Health Research Classification System category Neurological
Extra information provided by this PSP
Original uncertainty examples No examples provided.  This is an indicative uncertainty and several submissions were merged to form this one. 
Submitted by 2 patients ~ 3 carers ~ 4 clinicians
Outcomes to be measured Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs.
PSP information
PSP unique ID 0016
PSP name Multiple Sclerosis
Total number of uncertainties identified by this PSP. 82  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop July 2013